search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Aksanaku/www.shutterstock.com


Drug delivery Extending the


effect


Chronic diseases often come with a burden of administering medication routinely throughout the week, or in many cases, the day. Proponents of long-acting injectables wish to change this to make life easier for patients and increase medication adherence. Kim Thomas speaks to Farshad Ramazani, a principal researcher at Novartis, and Professor Andrew Owen, co-director of the Centre of Excellence for Long-acting Therapeutics at the University of Liverpool, to learn about long-acting injectables and the challenges researchers face in trying to bring them to the clinic.


F


or patients managing a chronic illness such as diabetes or schizophrenia, the need for a daily dose of medication creates additional burdens: remembering to take it; ordering and collecting a new prescription when it runs out; and making sure that they have enough medication to take with them when they go away on holiday or for short breaks. As Professor Andrew Owen, co-director of the Centre of Excellence for Long-acting Therapeutics (CELT) at the University of Liverpool, points out, when a patient forgets to take their medication, “this can compromise the efficacy of their therapy”. But what if we could remove those burdens? If, instead of taking a tablet every day, a patient could have a single injection that would last for months? The potential advantages aren’t difficult to imagine; their medication regime would be made easier, reducing the risk of harm caused by forgetting to take a dosage, or even forgetting one has already been taken and adding more of the active pharmaceutical ingredient to the body than it needs. On the other side of the equation, administering fewer injections would reduce the administrative load on doctors and pharmacists. In diseases that carry a social stigma, Owen points out, it would also provide patients with greater privacy.


10 World Pharmaceutical Frontiers / www.worldpharmaceuticals.net


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49